SCHEMBL9963405

SCHEMBL9963405

CC(C)N1CCN(Cc2nc3ccccc3o2)[C@@H](C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
USP2 O75604 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SLC6A9 P48067 1/20 0.38
DRD4 P21917 3/20 0.37
DRD3 P35462 2/20 0.37
DRD2 P14416 1/20 0.37
HTT P42858 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9966006 0.84 NPC1 (0.45) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL9933061 0.76 NPC1 (0.44) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL9963107 0.74 TBK1 (0.45) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL9934722 0.74 TBK1 (0.45) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL19967980 0.74 SLC6A9 (0.49) MAPTSLC6A9MEN1KMT2AHRH3
SCHEMBL9934812 0.72 KMT2A (0.46) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL9963404 0.71 LMNA (0.45) LMNASLC6A9DRD4KMT2AHRH3
SCHEMBL9963401 0.71 LMNA (0.45) LMNASLC6A9DRD4KMT2AHRH3
SCHEMBL10260303 0.67 SORD (0.58) MAPTSMN1; SMN2LMNAHTTKMT2A
SCHEMBL9963140 0.67 KCNH2 (0.47) MAPTLMNATP53USP2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 RAB9A 1162/4885NPC1 1934/4885MAPT 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.